MindMed

FCM Received Significant Support from Shareholders, Disappointed that “Passive” Investors Saw Fit to Give Incumbent Directors Another Chance to Disappoint

Retrieved on: 
Thursday, June 22, 2023
Pressure, MindMed, Management accounting, Face, AGM, FCM, Audit, Management

SHERIDAN, Wyo., June 22, 2023 (GLOBE NEWSWIRE) -- Today, FCM MM HOLDINGS, LLC (“FCM”) commented on Mind Medicine (MindMed) Inc.’s (NASDAQ: MNMD) (“MindMed” or the “Company”) announcement of preliminary results from the 2023 Annual General Meeting of Shareholders (“AGM”) and thanks fellow shareholders for their significant show of support at the AGM.

Key Points: 
  • FCM intends to continue fighting for all shareholders to prevent further value destruction at MindMed.
  • FCM is disappointed that “passive” institutional investors who purport to advocate for “ESG” policies turned a blind eye to serious ethical lapses by current management and saw fit to give incumbent directors another chance.
  • The issues we raised in our campaign, and indeed for over two years, have not gone away.
  • Our fellow shareholders can rest assured that FCM intends to remain a vigilant and engaged shareholder of MindMed.

MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

Retrieved on: 
Thursday, June 22, 2023
Biotechnology, Pharmaceutical, Health, Neurology, MindMed, NEO, Conference, EDT, Medicine, Pharmaceutical industry, Perfume

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference:

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference:
    Date and Time: Available as an on-demand session beginning on Monday, June 26, 2023 at 7:00 am EDT

MindMed Announces Election of All Six Company Nominees at Annual Meeting

Retrieved on: 
Wednesday, June 21, 2023
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, ISS, Meeting, Patient, Annual general meeting, Glass, NEO, Medicine, MindMed, Management, Security (finance)

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that, based upon a preliminary vote assessment, shareholders have elected all six of the Company’s nominees – CEO Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs and Carol A. Vallone – to the Board of Directors (the “Board”) at the Annual Meeting of Shareholders (the "Meeting") held today.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that, based upon a preliminary vote assessment, shareholders have elected all six of the Company’s nominees – CEO Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs and Carol A. Vallone – to the Board of Directors (the “Board”) at the Annual Meeting of Shareholders (the "Meeting") held today.
  • Robert Barrow, Chief Executive Officer and Director of MindMed, stated: “We would like to sincerely thank our shareholders for their support and engagement throughout this process.
  • The entire Board is fully committed to the Company’s success as we navigate this pivotal period, with two key clinical readouts expected later this year.
  • Final results will be filed on a Form 8-K with the U.S. Securities and Exchange Commission and will be filed with the Canadian securities regulatory authorities.

MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day

Retrieved on: 
Tuesday, June 20, 2023
Biotechnology, Pharmaceutical, Health, Anxiety, GAD, Medicine, Quality of life, Safety, NEO, MindMed, Pharmaceutical industry

-- David Feifel, MD, PhD (Kadima Neuropsychiatry Institute), who will discuss the practical aspects of administering monitored therapies

Key Points: 
  • Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, will provide an overview of clinical progress and corporate updates during an Investor Day today focused primarily on the MM-120 (lysergide D-tartrate) program in generalized anxiety disorder (GAD).
  • The Investor Day will begin at 9:30 a.m.
  • Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Resources website for up to 90 days following the event.
  • In May 2023, the Company reported that over 50% of the target study population has been enrolled and dosed.

FCM Denounces MindMed’s Manipulation of Corporate Machinery to Protect Incumbent Board of Directors

Retrieved on: 
Thursday, June 15, 2023
BLUE, MindMed, Face, AGM, LSD, Patient, FDA, FCM, Security (finance), Holding company

SHERIDAN, Wyo., June 15, 2023 (GLOBE NEWSWIRE) -- Today, FCM MM Holdings, LLC (“FCM”) condemns Mind Medicine (MindMed) Inc.’s (NASDAQ: MNMD) (“MindMed”, the “Company”) announced apparent plan to manipulate its corporate machinery to follow through with its 2023 annual general meeting (the “AGM”) and election of directors without earning the substantive support of its shareholders.

Key Points: 
  • FCM contends this extraordinarily low level of shareholder participation reflects deep shareholder dissatisfaction and MindMed’s persistent refusal to meaningfully engage with shareholders.
  • Now, MindMed says that whoever shows up at its adjourned AGM – even a single share – will be enough!
  • It is unfortunate, but not surprising, that the board would take inappropriate actions which imperil MindMed’s future to protect the entrenched board,” says Mr. Vivek Jain, FCM nominee.
  • Shareholders who have questions or require any assistance with their vote, please contact Okapi Partners LLC, at (855) 305-0856 or [email protected] .

MindMed Adjourns Annual General Meeting of Shareholders

Retrieved on: 
Thursday, June 15, 2023
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, NOT, Eastern Time Zone, Annual Meetings of the International Monetary Fund and the World Bank Group, Meeting, Annual general meeting, NEO, Proxy, Proxy firm, Medicine, MindMed, FCM, Security (finance), Auction

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that the Company’s Annual General Meeting of Shareholders (the “Meeting”) on June 15, 2023 was convened at 10:00 a.m. (Eastern Time) and adjourned, without any business being conducted, due to lack of the required quorum.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that the Company’s Annual General Meeting of Shareholders (the “Meeting”) on June 15, 2023 was convened at 10:00 a.m. (Eastern Time) and adjourned, without any business being conducted, due to lack of the required quorum.
  • As is customary, the Company expected all of these shares to be present at the Meeting.
  • The Company believes representatives of FCM MM Holdings, LLC deliberately acted to prevent the voices of all shareholders from being heard and the business of the Meeting from being completed.
  • Shareholders who access the reconvened Meeting virtually and vote on any matter will revoke any previously submitted proxy card.

FCM Calls for Socially Responsible Investors to Vote for Change at MindMed

Retrieved on: 
Friday, June 9, 2023
BLUE, Drug development, DSM-IV codes, LSD, CMO, CNS, Consultant, Patient, Patient safety, Phase, FDA, Safety, MindMed, FCM, Security (finance), Pharmaceutical industry

Dr. Freeman and Other FCM Directors Pledge to Extend Lockup Period for Selling Shares Until June 15, 2026

Key Points: 
  • Dr. Freeman and Other FCM Directors Pledge to Extend Lockup Period for Selling Shares Until June 15, 2026
    SHERIDAN, Wyo., June 09, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), representing approximately 3.5% of the outstanding common shares of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (“MindMed” or the “Company”), calls for socially responsible investors to vote for change at MindMed.
  • Although investing in companies like MindMed is ultimately about generating a positive return, FCM and many other influential investors believe there should be a social conscience element involved in investing too.
  • However, Dr. Freeman was immediately suspended from his position as CMO by the MindMed board and management three hours after stopping the study.
  • FCM’s director candidates meet both financial and socially responsible investing standards and we need your support to make urgent changes at MindMed,” said FCM Nominee Dr. Freeman.

FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026

Retrieved on: 
Wednesday, June 7, 2023
GAD, LSD, CNS, Patient, Phase, FDA, III, Mouth, MindMed, FCM, Pharmaceutical industry

SHERIDAN, Wyo., June 07, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), representing approximately 3.5% of the outstanding common shares of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (“MindMed” or the “Company”), announces Dr. Freeman and the other FCM nominees, will extend their lockup period for selling shares until June 2026 in anticipation of bringing MM-120 (LSD) to market in 2026 after completing the phase III study.

Key Points: 
  • “We put our money where our mouth is, unlike the current management who appears to sell shares monthly,” said Dr. Scott Freeman.
  • Current management is ensconced in an unnecessary Phase IIb dose finding study which will take longer to bring MM-120 to market (after 2026).
  • However, based on FCM’s capital realignment plans, FCM will be able pay for the Phase III study without further dilution with the expectation of gaining approval by 2026.
  • Shareholders who have questions or require any assistance with their vote, please contact Okapi Partners LLC, at (855) 305-0856 or [email protected]

MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline

Retrieved on: 
Friday, June 9, 2023
Biotechnology, Neurology, Mental Health, Health, Clinical Trials, Medicine, Annual general meeting, NOT, Multimedia, Patient, NEO, MindMed, FCM, Security (finance)

MindMed urges shareholders to vote online ahead of the deadline to ensure that their shares are represented.

Key Points: 
  • MindMed urges shareholders to vote online ahead of the deadline to ensure that their shares are represented.
  • MindMed is confident that its nominees possess relevant backgrounds and expertise to continue overseeing the Company’s strategy and remains focused on its mission to deliver value to patients and shareholders.
  • The inclusion of FCM’s nominees on our WHITE proxy card does NOT mean the Board endorses them.
  • Vote TODAY on the WHITE proxy card FOR all six of the Board’s nominees, WITHHOLD on FCM’s nominees and FOR the other proposals recommended by your Board.

Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees

Retrieved on: 
Thursday, June 8, 2023
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, GAD, MindMed, NOT, ALL, Medicine, Glass Lewis, Annual general meeting, Patient, Glass, FDA, NEO, ISS, FCM, Management, Security (finance)

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today announced that leading proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends shareholders vote for the election of ALL of MindMed’s six highly qualified director nominees to the Board of Directors (the “Board”) at the upcoming Annual Meeting of Shareholders (“Annual Meeting”), scheduled for June 15, 2023.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today announced that leading proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends shareholders vote for the election of ALL of MindMed’s six highly qualified director nominees to the Board of Directors (the “Board”) at the upcoming Annual Meeting of Shareholders (“Annual Meeting”), scheduled for June 15, 2023.
  • Previously, leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) also recommended in favor of all six of the Company’s director nominees.
  • Vote TODAY on the WHITE proxy card FOR all six of the Board’s nominees, WITHHOLD on FCM’s nominees and FOR the other proposals recommended by your Board.
  • Shareholders will receive proxy materials directly via the preferred method, hard copy or email, specific to each shareholder’s account.